Competitive Rivalry

COVID vaccine demand has normalized sharply, leaving Novavax to compete in a shrinking, highly commoditized market against Pfizer, Moderna, and GSK, which compresses pricing power.

Unlike diversified peers with large respiratory franchises, Novavax remains concentrated in a single product category, so rivalry translates more directly into margin pressure and weaker scale economics.

The company’s smaller commercial footprint limits its ability to absorb launch, manufacturing, and SG&A costs versus larger peers, making industry rivalry more damaging to profitability.

Threat Of New Entrants

Regulatory, clinical, and manufacturing barriers remain high in vaccines, so new entrants face long timelines and capital intensity that protect incumbents like Novavax relative to biotech startups.

Established global players with existing cold-chain, procurement, and pharmacovigilance infrastructure can enter faster than de novo entrants, but this advantage is shared by larger peers rather than unique to Novavax.

The need for validated adjuvant and antigen manufacturing capabilities limits greenfield competition, which supports industry structure and reduces the likelihood of rapid price erosion.

Bargaining Power Of Suppliers

Novavax relies on specialized biologics manufacturing, fill-finish, and raw-material inputs, so supplier concentration can raise unit costs and constrain gross margin more than for vertically integrated peers.

Because the company lacks the scale of Pfizer or GSK, it has less leverage in contract manufacturing negotiations, making supplier pricing and capacity terms more binding on profitability.

Any disruption in qualified vaccine supply partners can force costly revalidation or inventory actions, increasing structural cost volatility versus larger competitors with broader sourcing options.

Bargaining Power Of Buyers

Large public-health buyers, governments, and procurement agencies dominate vaccine purchasing, so Novavax faces concentrated demand-side pricing pressure and limited ability to defend list prices.

Buyers can compare Novavax directly with Pfizer, Moderna, and GSK on efficacy, availability, and contract terms, which weakens Novavax’s negotiating position versus larger peers.

As COVID vaccine volumes fall, buyers gain more leverage over allocation and pricing, while Novavax’s narrower portfolio reduces cross-selling power and contract stickiness.

Threat Of Substitutes

For respiratory immunization, substitutes include competing mRNA and protein-based vaccines, and buyers can switch among them with limited switching costs, pressuring Novavax’s pricing power.

As infection risk becomes more seasonal and heterogeneous, some consumers and payers may defer vaccination altogether, which acts as a substitute and reduces industry-wide demand intensity.

Compared with diversified peers that can offset substitution in one franchise with others, Novavax bears the full margin impact when alternative vaccines or no-vaccine choices gain share.

Overall Score

Novavax operates in a structurally tough vaccine market where buyer power, rivalry, and substitutes materially compress pricing power, while supplier dependence adds further margin pressure versus larger global peers.